GlaxoSmithKline Pharmaceuticals Limited Stock price

Equities

GLAXO

INE159A01016

Pharmaceuticals

Market Closed - Bombay S.E. 05:01:06 2024-02-09 am EST 5-day change 1st Jan Change
2,380 INR -1.57% Intraday chart for GlaxoSmithKline Pharmaceuticals Limited +3.58% +25.41%
Sales 2024 * 34.46B 415M Sales 2025 * 37.35B 450M Capitalization 403B 4.86B
Net income 2024 * 6.82B 82.13M Net income 2025 * 7.46B 89.95M EV / Sales 2024 * 11.7 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 10.8 x
P/E ratio 2024 *
58.6 x
P/E ratio 2025 *
54 x
Employees 3,680
Yield 2024 *
1.27%
Yield 2025 *
1.33%
Free-Float 24.41%
More Fundamentals * Assessed data
Dynamic Chart
GlaxoSmithKline Pharmaceuticals Limited Announces Resignation of Sunder Ramachandran as Head of Commercial Excellence, Effective 12 January 2024 CI
GlaxoSmithKline Pharmaceuticals Limited Announces Resignation of Abhinav Kashyap as Pharma Technology Lead CI
GSK's India unit posts Q2 profit rise on strong vaccine demand RE
GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
GlaxoSmithKline Pharmaceuticals Limited Appoints Omkar Parnandiwar as Head of Omnichannel, Effective November 1, 2023 CI
Glaxosmithkline Pharmaceuticals Records Rise in Fiscal Q1 Consolidated Net Profit MT
India's GlaxoSmithKline Pharma posts rise in Q1 profit on steady vaccine business RE
GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Samsung Biologics unveils $920 mln manufacturing deals for Pfizer RE
A son died, his parents tried to sue. How U.S. courts protect Big Pharma RE
Abbott's India arm posts 9.5% rise in fourth-quarter profit RE
GlaxoSmithKline Pharmaceuticals's Net Profit Slumps in Fiscal Q4 MT
India's GlaxoSmithKline Pharma's pre-tax profit falls on govt pricing caps RE
GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
GlaxoSmithKline Pharmaceuticals Limited Proposes Final Dividend for the Year Ended March 31, 2023 CI
More news

Latest transcript on GlaxoSmithKline Pharmaceuticals Limited

1 day-1.57%
1 week+3.58%
Current month+5.86%
1 month+8.08%
3 months+61.35%
6 months+66.16%
Current year+25.41%
More quotes
1 week
2 210.00
Extreme 2210
2 649.95
1 month
2 140.00
Extreme 2140
2 649.95
Current year
1 952.65
Extreme 1952.65
2 649.95
1 year
1 228.00
Extreme 1228
2 649.95
3 years
1 228.00
Extreme 1228
2 649.95
5 years
1 046.40
Extreme 1046.4
2 649.95
10 years
1 020.00
Extreme 1020
2 649.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 22-11-30
Director of Finance/CFO - 22-03-31
Compliance Officer - -
Members of the board TitleAgeSince
Chairman 70 19-03-31
Director/Board Member 64 22-05-15
Director/Board Member 74 15-03-29
More insiders
Date Price Change Volume
24-02-09 2,380 -1.57% 3,965
24-02-08 2,418 -0.44% 5,606
24-02-07 2,428 -1.56% 3,438
24-02-06 2,467 +0.72% 16,628
24-02-05 2,449 +6.61% 13,363

Delayed Quote Bombay S.E., February 09, 2024 at 05:01 am EST

More quotes
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. It has three product areas: vaccines, specialty and general medicines. Its general medicines business has a portfolio of medicines in anti-infectives, pain, dermatology and vitamins. Its general medicines brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact and Physiogel. Its T-bact brand products are used in specific types of bacterial skin infections. The Company's vaccine brands include Shingrix, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicines business is focused on developing medicines for respiratory diseases and human immunodeficiency virus. The Company is also building its presence in other therapeutic areas, such as immunology and oncology. Its specialty medicines brands include Nucala and Trelegy Ellipta.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2,380 INR
Average target price
1,857 INR
Spread / Average Target
-21.95%
Consensus
1st Jan change Capi.
+25.41% 4 856 M $
+26.97% 666 B $
+19.17% 536 B $
+0.01% 377 B $
+15.07% 318 B $
+12.33% 307 B $
-8.02% 207 B $
+4.05% 206 B $
-7.92% 191 B $
-4.27% 156 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock GlaxoSmithKline Pharmaceuticals Limited - Bombay S.E.
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer